Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report
-
Published:2024-02
Issue:
Volume:51
Page:101322
-
ISSN:2352-5789
-
Container-title:Gynecologic Oncology Reports
-
language:en
-
Short-container-title:Gynecologic Oncology Reports
Author:
St. Laurent Jessica D., Kathryn Abel Mary, Liu Joyce, Quade Bradley J., Davis Michelle R.ORCID
Reference12 articles.
1. Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship;Ardighieri;Virchows Arch.,2016 2. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma;Berton-Rigaud;Int. J. Gynecol. Cancer.,2014 3. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention;Carlson;J. Clin. Oncol.,2008 4. DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023 Jan 20;41(3):609-617. doi: 10.1200/JCO.22.01549. Epub 2022 Sep 9. PMID: 36082969; PMCID: PMC9870219. 5. Current management of ovarian carcinosarcoma;Mano;Int. J. Gynecol. Cancer.,2007
|
|